PACS Group (NYSE:PACS) Director Mark Hancock Sells 155,682 Shares of Stock

PACS Group, Inc. (NYSE:PACS) Director Mark Hancock sold 155,682 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $42.47, for a total value of $6,611,814.54. Following the completion of the sale, the director owned 53,518,884 shares in the company, valued at $2,272,947,003.48. The trade was a 0.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hancock also recently made the following trade(s):

• On Monday, September 14th, Mark Hancock sold 144,318 shares of PACS Group stock. The shares were sold at an average price of $44.57, for a total transaction of $6,432,253.26.
• On Thursday, July 9th, Mark Hancock sold 4,966 shares of PACS Group stock. The stock was sold at an average price of $45.06, for a total transaction of $223,767.96.
• On Wednesday, July 8th, Mark Hancock sold 20,338 shares of PACS Group stock. The stock was sold at an average price of $45.07, for a total transaction of $916,633.66.
• On Monday, July 6th, Mark Hancock sold 142,163 shares of PACS Group stock. The shares were sold at an average price of $45.33, for a total transaction of $6,444,248.79.
• On Thursday, July 2nd, Mark Hancock sold 12,825 shares of PACS Group stock. The shares were sold at an average price of $45.01, for a total transaction of $577,253.25.
• On Wednesday, July 1st, Mark Hancock sold 6,080 shares of PACS Group stock. The shares were sold at an average price of $45.02, for a total transaction of $273,721.60.
• On Friday, June 26th, Mark Hancock sold 61,931 shares of PACS Group stock. The stock was sold at an average price of $40.50, for a total transaction of $2,508,205.50.
• On Thursday, June 25th, Mark Hancock sold 138,069 shares of PACS Group stock. The stock was sold at an average price of $40.33, for a total transaction of $5,568,322.77.
• On Wednesday, June 17th, Mark Hancock sold 63,680 shares of PACS Group stock. The shares were sold at an average price of $35.31, for a total transaction of $2,248,540.80.

PACS Group Stock Performance

Shares of PACS traded down $2.54 during mid-day trading on Tuesday, reaching $42.01. 1,011,870 shares of the company’s stock traded hands, compared to its average volume of 905,184. The business’s 50-day moving average price is $44.74 and its 200-day moving average price is $39.12. The stock has a market capitalization of $6.65 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 1.40 and a beta of -0.13. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.91 and a current ratio of 0.91. PACS Group, Inc. has a 12 month low of $10.31 and a 12 month high of $49.49.

PACS Group (NYSE:PACS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.09. PACS Group had a return on equity of 29.55% and a net margin of 4.85%.The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.41 billion. Equities analysts predict that PACS Group, Inc. will post 2.13 earnings per share for the current year.

Trending Headlines about PACS Group

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Investor Steven Cress highlighted PACS Group as a highly rated stock he owns, reinforcing the bullish case for the skilled-nursing and post-acute-care operator. Behind The Portfolio: Why Steven Cress Owns This Top-Rated Stock
• Positive Sentiment: Analyst sentiment remains favorable: PACS has a consensus “Moderate Buy” rating and an average price target of $58.80, above recent trading levels. Truist, Oppenheimer, UBS and JPMorgan have recently set targets ranging from $57 to $62. The company also exceeded second-quarter earnings and revenue expectations, reporting adjusted earnings of $0.63 per share versus the $0.54 consensus and revenue of $1.43 billion versus $1.41 billion.
• Neutral Sentiment: PACS announced that CEO and Chairman Jason Murray, CFO Carey Hendrickson and COO Josh Jergensen will present at the Jefferies Healthcare Services and Technology Conference on September 15. Investors may look for updates on operations, growth plans and the company’s outlook. PACS Group to Present at the 2026 Jefferies Healthcare Services and Technology Conference
• Negative Sentiment: CEO Jason Murray continued selling shares under a pre-arranged Rule 10b5-1 plan, including 317 shares at $45.03 and earlier sales of 10,529 shares at $45.23 and 8,771 shares at $45.16. The sales can weigh on sentiment, although they represent a very small portion of his roughly 54.6 million remaining shares and do not necessarily signal deteriorating business prospects. Insider Selling: PACS Group CEO Sells 317 Shares

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. acquired a new stake in shares of PACS Group during the first quarter valued at approximately $3,171,000. Smith Group Asset Management LLC acquired a new stake in shares of PACS Group during the 1st quarter valued at $771,000. Maven Securities LTD purchased a new position in shares of PACS Group during the 4th quarter valued at $960,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of PACS Group in the first quarter worth $6,762,000. Finally, Corient Private Wealth LLC increased its stake in shares of PACS Group by 29.7% in the fourth quarter. Corient Private Wealth LLC now owns 170,052 shares of the company’s stock worth $6,528,000 after acquiring an additional 38,956 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PACS shares. Weiss Ratings downgraded shares of PACS Group from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, August 5th. Truist Financial set a $62.00 target price on shares of PACS Group in a research note on Wednesday, September 2nd. UBS Group boosted their price target on shares of PACS Group from $57.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Royal Bank Of Canada upped their price target on shares of PACS Group from $52.00 to $57.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of PACS Group from $47.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, PACS Group presently has an average rating of “Moderate Buy” and an average target price of $58.80.

PACS Group Company Profile

PACS Group, Inc is a U.S. healthcare services company that operates skilled nursing and post-acute care facilities. Its facilities provide short-term rehabilitation, long-term skilled nursing, nursing care, and related clinical services for patients recovering from illness, injury, surgery, or hospitalization.

The company’s broader care offerings may include assisted living, memory care, behavioral health, and other specialized post-acute services, depending on the facility and market.